Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOXA2/AP-1 drives prostate cancer lineage plasticity

ABSTRACT: FOXA2/AP-1 drives prostate cancer lineage plasticity

PROVIDER: PRJNA972713 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24572400_1.fastq.gz	Fastqsanger.gz
	SRR24572400_2.fastq.gz	Fastqsanger.gz
	SRR24572500.fastq.gz	Fastqsanger.gz
	SRR24572401_1.fastq.gz	Fastqsanger.gz
	SRR24572401_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 202

Similar Datasets

FOXA2/AP-1 drives prostate cancer lineage plasticity [ChIP-seq]

Project description:FOXA2/AP-1 drives prostate cancer lineage plasticity [ChIP-seq]

| PRJNA972717 | ENA

FOXA2/AP-1 drives prostate cancer lineage plasticity [RNA-seq]

Project description:FOXA2/AP-1 drives prostate cancer lineage plasticity [RNA-seq]

| PRJNA972718 | ENA

FOXA2/AP-1 drives prostate cancer lineage plasticity [RNA-seq]

Project description:FOXA (Forkhead Box Protein A) family proteins function as pioneer transcription factors by loosening the compact chromatin structure and facilitating access for other transcription factors. The role of FOXA1 has been intensively studied in normal prostate epithelial cells and the adenocarcinoma subtype of prostate cancer (PCa) where it acts as a critical pioneer factor for the chromatin binding of androgen receptor (AR). Recent studies have indicated the emergence of FOXA2 as an adaptive response to AR signaling inhibition, particularly in prostate tumors that have undergone lineage reprogramming to a neuroendocrine PCa subtype. However, the molecular basis for this transition from FOXA1 to FOXA2 and its role in regulating the development of PCa lineage plasticity remains unclear. In this study, we show that FOXA2 binds to distinct chromatin regions in multiple AR-null PCa models with different molecular subtypes and that its binding is dependent on an epigenetic factor, LSD1. More importantly, we demonstrate that FOXA2 can function as a major pioneer factor of JUN and govern the chromatin binding of AP-1 complex in PCa exhibiting lineage plasticity. Mechanistically, differential reprogramming of JUN activates lineage-specific super-enhancers that may promote PCa progression by enhancing cell state transitions to multiple lineages. Overall, our study reveals a pivotal function of the LSD1-FOXA2 axis in rewiring AP-1 to induce differential transcriptional reprogramming required for PCa lineage plasticity.

2024-04-22 | GSE232554 | GEO

FOXA2/AP-1 drives prostate cancer lineage plasticity [ChIP-seq]

2024-04-22 | GSE232552 | GEO

FOXA2/AP-1 drives prostate cancer lineage plasticity [PDX ChIP-seq]

2024-04-22 | GSE232553 | GEO

FOXA2/AP-1 drives prostate cancer lineage plasticity [PDX ChIP-seq]

Project description:FOXA2/AP-1 drives prostate cancer lineage plasticity [PDX ChIP-seq]

| PRJNA972716 | ENA

FOXA2/AP-1 drives prostate cancer lineage plasticity

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-04-22 | GSE232555 | GEO

FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer

Project description:For FLAG pull-down, protein extracts of cells stably expressing FLAG-tagged FOXA2 were incubated with FLAG-conjugated beads. To perform mass spectrometry analysis, we used at least 6 x 108 cells to map post-translational modification sites through Thermo EASY-nLC 1200 at the Proteomics Core of University of Massachusetts Boston

2024-05-15 | MSV000094773 | MassIVE

PlexinD1 drives the lineage plasticity in advanced prostate cancer

Project description:PlexinD1 drives the lineage plasticity in advanced prostate cancer

| PRJNA1067089 | ENA

Targeting FOXA1 and FOXA2 Disrupts the Lineage-Specific Oncogenic Output in Prostate Cancer [ChIP-seq]

Project description:Activation of the androgen receptor (AR) is the key lineage-specific oncogenic pathway and the primary therapeutic target in prostate cancer. While AR signaling is enabled by the pioneer transcription factor FOXA1, its homologue FOXA2 is specifically expressed in advanced lineage plasticity prostate cancers that have lost the AR signaling axis. However, their roles and utility as a drug target remain incompletely characterized. Here, we show an unexpected collaboration of FOXA1 and FOXA2 in mediating AR-independent cell proliferation in different lineage plasticity cancer subtypes. Conversely, joint loss-of-function or pharmacologic disruption of FOXA1 and FOXA2 leads to the collapse of lineage-specific oncogenic transcription factors followed by cell cycle arrest. In summary, our findings uncover a druggable dependency for AR-positive and -negative prostate cancers.

2025-08-30 | GSE281784 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data